A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report

We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient’s tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yi, Zhang, Hao, Shi, Junfeng, Wang, Tongshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721275/
https://www.ncbi.nlm.nih.gov/pubmed/33299330
http://dx.doi.org/10.2147/OTT.S279004
_version_ 1783620005609340928
author Chen, Yi
Zhang, Hao
Shi, Junfeng
Wang, Tongshan
author_facet Chen, Yi
Zhang, Hao
Shi, Junfeng
Wang, Tongshan
author_sort Chen, Yi
collection PubMed
description We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient’s tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of chemotherapy. Fortunately, the tumors dramatically shrank after one cycle of camrelizumab, an anti-programmed cell death-1 (PD-1) antibody developed by Chinese Hengrui Medicine. In conclusion, camrelizumab may be a good treatment option, especially in tumors that express PD-L1.
format Online
Article
Text
id pubmed-7721275
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77212752020-12-08 A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report Chen, Yi Zhang, Hao Shi, Junfeng Wang, Tongshan Onco Targets Ther Case Report We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient’s tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of chemotherapy. Fortunately, the tumors dramatically shrank after one cycle of camrelizumab, an anti-programmed cell death-1 (PD-1) antibody developed by Chinese Hengrui Medicine. In conclusion, camrelizumab may be a good treatment option, especially in tumors that express PD-L1. Dove 2020-12-03 /pmc/articles/PMC7721275/ /pubmed/33299330 http://dx.doi.org/10.2147/OTT.S279004 Text en © 2020 Chen et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Chen, Yi
Zhang, Hao
Shi, Junfeng
Wang, Tongshan
A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
title A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
title_full A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
title_fullStr A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
title_full_unstemmed A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
title_short A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
title_sort partial response of pulmonary pleomorphic carcinoma to camrelizumab (pd1 monoclonal antibody) monotherapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721275/
https://www.ncbi.nlm.nih.gov/pubmed/33299330
http://dx.doi.org/10.2147/OTT.S279004
work_keys_str_mv AT chenyi apartialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport
AT zhanghao apartialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport
AT shijunfeng apartialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport
AT wangtongshan apartialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport
AT chenyi partialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport
AT zhanghao partialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport
AT shijunfeng partialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport
AT wangtongshan partialresponseofpulmonarypleomorphiccarcinomatocamrelizumabpd1monoclonalantibodymonotherapyacasereport

Ejemplares similares